Brett Heier's attorney Barry Sheppard says his client is only accused of spitting on the agent's shoe and his actions fall ...

Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial ...

A West Texas A&M University assistant professor of animal science, Dr. Emilie Baker, was awarded a grant from the U.S.

The Massachusetts Dental Society recently urged the House budget chief to reconsider Healey’s proposed cap and avoid making ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Sarah Williams was diagnosed with pancreatic cancer after doctors initially dismissed her symptoms and advised her to take ...

Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...

Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. HS, a chronic, recurrent ...

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses ...

Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease causing boils, as well as draining abscesses and sinus ...